{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:43:45Z","timestamp":1791413025587,"version":"4.3.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100030684","name":"Maruho","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01554-4","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:57:23Z","timestamp":1759175843000},"page":"3615-3632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1628-4979","authenticated-orcid":false,"given":"Tomoki","family":"Takechi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Ieiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"1554_CR1","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/bjd\/ljae052","volume":"190","author":"V Liao","year":"2024","unstructured":"Liao V, Cornman HL, Ma E, Kwatra SG. Prurigo nodularis: new insights into pathogenesis and novel therapeutics. Br J Dermatol. 2024;190:798\u2013810.","journal-title":"Br J Dermatol"},{"key":"1554_CR2","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","volume":"83","author":"AH Huang","year":"2020","unstructured":"Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83:1559\u201365.","journal-title":"J Am Acad Dermatol"},{"key":"1554_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4103\/idoj.IDOJ_324_17","volume":"9","author":"L Dhawan","year":"2018","unstructured":"Dhawan L, Singh SM, Avasthi A, Kumaran MS, Narang T. The prevalence of psychiatric comorbidity in patients with prurigo nodularis. Indian Dermatol Online J. 2018;9:318\u201321.","journal-title":"Indian Dermatol Online J"},{"key":"1554_CR4","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3778","volume":"101","author":"EC Gwillim","year":"2021","unstructured":"Gwillim EC, Nattkemper L, Yosipovitch G. Impact of itch on sleep disturbance in patients with prurigo nodularis. Acta Derm Venereol. 2021;101:adv00424.","journal-title":"Acta Derm Venereol"},{"key":"1554_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","volume":"140","author":"AH Huang","year":"2020","unstructured":"Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2020;140:480-483.e4.","journal-title":"J Invest Dermatol"},{"key":"1554_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/ITT.S316602","volume":"11","author":"A Labib","year":"2022","unstructured":"Labib A, Ju T, Vander Does A, Yosipovitch G. Immunotargets and therapy for prurigo nodularis. Immunotargets Ther. 2022;11:11\u201321.","journal-title":"Immunotargets Ther"},{"key":"1554_CR7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/exd.14279","volume":"30","author":"T Hashimoto","year":"2021","unstructured":"Hashimoto T, Nattkemper LA, Kim HS, et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol. 2021;30:804\u201310.","journal-title":"Exp Dermatol"},{"key":"1554_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","volume":"117","author":"E Sonkoly","year":"2006","unstructured":"Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T\u00a0cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117:411\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1554_CR9","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","volume":"12","author":"A Kuzumi","year":"2021","unstructured":"Kuzumi A, Yoshizaki A, Matsuda KM, et al. Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nat Commun. 2021;12:5947.","journal-title":"Nat Commun"},{"key":"1554_CR10","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1093\/rheumatology\/keaa195","volume":"59","author":"B Yaseen","year":"2020","unstructured":"Yaseen B, Lopez H, Taki Z, et al. Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatology. 2020;59:2625\u201336.","journal-title":"Rheumatology"},{"key":"1554_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40265-022-01741-z","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Nemolizumab: first approval. Drugs. 2022;82:1143\u201350.","journal-title":"Drugs"},{"key":"1554_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/1744666X.2024.2306225","volume":"20","author":"SG Brooks","year":"2024","unstructured":"Brooks SG, Yosipovitch G. A critical evaluation of nemolizumab for prurigo nodularis. Expert Rev Clin Immunol. 2024;20:577\u201387.","journal-title":"Expert Rev Clin Immunol"},{"key":"1554_CR13","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jaci.2024.02.016","volume":"153","author":"BS Kim","year":"2024","unstructured":"Kim BS. Learning from nemolizumab: a promising therapy for prurigo nodularis. J Allergy Clin Immunol. 2024;153:1548\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"1554_CR14","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","volume":"389","author":"SG Kwatra","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, et al. Phase\u00a03 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389:1579\u201389.","journal-title":"N Engl J Med"},{"key":"1554_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","volume":"161","author":"S St\u00e4nder","year":"2025","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, et al. Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase\u00a03 trial. JAMA Dermatol. 2025;161:147\u201356.","journal-title":"JAMA Dermatol"},{"key":"1554_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/bjd\/ljae131","volume":"191","author":"H Yokozeki","year":"2024","unstructured":"Yokozeki H, Murota H, Matsumura T, Komazaki H, Nemolizumab-JP11 study group. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase\u00a0II\/III clinical study in patients aged \u2265 13\u00a0years [published correction appears in Br J Dermatol. 2024 Nov 18; 191:e26\u2013e27.]. Br J Dermatol. 2024;191:200\u20138.","journal-title":"Br J Dermatol"},{"key":"1554_CR17","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase\u00a03 trials. Nat Med. 2023;29:1180\u201390.","journal-title":"Nat Med"},{"key":"1554_CR18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/clpt.2011.242","volume":"90","author":"JW Mandema","year":"2011","unstructured":"Mandema JW, Gibbs M, Boyd RA, Wada DR, Pfister M. Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond. Clin Pharmacol Ther. 2011;90:766\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1554_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/clpt.2012.122","volume":"92","author":"DR Mould","year":"2012","unstructured":"Mould DR. Model-based meta-analysis: an important tool for making quantitative decisions during drug development. Clin Pharmacol Ther. 2012;92(3):283\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"1554_CR20","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/jcph.969","volume":"57","author":"T Saito","year":"2017","unstructured":"Saito T, Iida S, Terao K, Kumagai Y. Dosage optimization of nemolizumab using population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling and simulation. J Clin Pharmacol. 2017;57:1564\u201372.","journal-title":"J Clin Pharmacol"},{"key":"1554_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181:761\u20139.","journal-title":"Br J Dermatol"},{"key":"1554_CR22","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3701","volume":"101","author":"C Zeidler","year":"2021","unstructured":"Zeidler C, Pereira MP, Augustin M, Spellman M, St\u00e4nder S. Investigator\u2019s global assessment of chronic prurigo: a new instrument for use in clinical trials. Acta Derm Venereol. 2021;101:adv00401.","journal-title":"Acta Derm Venereol"},{"key":"1554_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1554_CR24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","volume":"382","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020;382:706\u201316.","journal-title":"N Engl J Med"},{"key":"1554_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633\u201359.","journal-title":"Clin Pharmacokinet"},{"key":"1554_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/clpt.2012.69","volume":"92","author":"I Demin","year":"2012","unstructured":"Demin I, Hamr\u00e9n B, Luttringer O, Pillai G, Jung T. Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development. Clin Pharmacol Ther. 2012;92:352\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1554_CR27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10928-023-09853-z","volume":"50","author":"C Llanos-Paez","year":"2023","unstructured":"Llanos-Paez C, Ambery C, Yang S, Beerahee M, Plan EL, Karlsson MO. Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials. J Pharmacokinet Pharmacodyn. 2023;50:297\u2013314.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1554_CR28","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jid.2023.12.003","volume":"144","author":"XY Wang","year":"2024","unstructured":"Wang XY, Jia QN, Wu MY, Liu MJ, Mi X, Li J. Comparing the efficacy of updated treatment choices for prurigo nodularis: a network meta-analysis. J Invest Dermatol. 2024;144:1409-1412.e7.","journal-title":"J Invest Dermatol"},{"key":"1554_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ad.2021.12.014","volume":"113","author":"E Serra-Baldrich","year":"2022","unstructured":"Serra-Baldrich E, Santamar\u00eda-Bab\u00ed LF, Francisco Silvestre J. Nemolizumab: an innovative biologic treatment to control interleukin 31, a key mediator in atopic dermatitis and prurigo nodularis. Actas Dermo-Sifiliogr. 2022;113:674\u201384.","journal-title":"Actas Dermo-Sifiliogr"},{"key":"1554_CR30","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s10787-024-01436-9","volume":"32","author":"MA Nilforoushzadeh","year":"2024","unstructured":"Nilforoushzadeh MA, Heidari N, Ghane Y, et al. A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis. Inflammopharmacology. 2024;32:991\u20131003.","journal-title":"Inflammopharmacology"},{"key":"1554_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.638325","volume":"8","author":"K Kabashima","year":"2021","unstructured":"Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. Front Med. 2021;8:638325.","journal-title":"Front Med"},{"key":"1554_CR32","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jaci.2021.10.004","volume":"149","author":"LC Tsoi","year":"2022","unstructured":"Tsoi LC, Hacini-Rachinel F, Fogel P, et al. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J Allergy Clin Immunol. 2022;149:1329\u201339.","journal-title":"J Allergy Clin Immunol"},{"key":"1554_CR33","unstructured":"Puelles J, de la Cruz M, Murphy R, Devlen J, Gabriel S. Qualitative equivalence of the worst itch and peak pruritus numerical rating scales in prurigo nodularis [poster]. In: European Academy of Dermatology and Venereology, EADV 35th Congress, 29 Sept to 02 Oct 2021 (2021)."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01554-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:22:11Z","timestamp":1763198531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01554-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1554"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01554-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tomoki Takechi and Junya Shimizu are employees of Maruho Co., Ltd. Kenji Kabashima has received consulting fees, honoraria, grant support, and\/or lecture fees from AbbVie, Amgen, Eli Lilly, Kyowa Kirin, Japan Tobacco, LEO Pharma, Maruho, Mitsubishi Tanabe, Ono Pharmaceutical, Pfizer, Procter & Gamble, Sanofi, Regeneron, Taiho, and Torii Pharmaceutical. Ichiro Ieiri has received fees from the company for consultation, lectures, and writing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All clinical trials included in this pooled analysis were approved by their respective independent ethics committees, and all participants provided written informed consent in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}